Business Wire

Datopotamab Deruxtecan Showed Encouraging and Durable Efficacy in Patients with Heavily Pretreated HR Positive, HER2 Low or Negative Metastatic Breast Cancer

Share

Initial results from the TROPION-PanTumor01 phase 1 trial of datopotamab deruxtecan (Dato-DXd) showed encouraging and durable efficacy in patients with heavily pretreated hormone receptor (HR) positive, HER2 low (immunohistochemistry [IHC] 1+ or IHC 2+/in-situ hybridization [ISH]-) or HER2 negative (IHC 0) unresectable or metastatic breast cancer. Safety data were consistent with previous trials of datopotamab deruxtecan. Results were presented today as a Spotlight Poster Discussion (Abstract #PD13-08) at the 2022 San Antonio Breast Cancer Symposium (#SABCS22).

Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) being jointly developed by Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN).

Approximately 70% of breast cancer tumors are considered HR positive and HER2 low or negative.1 For patients with HR positive, HER2 low or negative metastatic breast cancer that progress on or are not suitable candidates for endocrine therapy, the current standard of care is single-agent chemotherapy.2

In this cohort of TROPION-PanTumor01 (n=41) where patients previously received a median of five lines of treatment for metastatic disease, datopotamab deruxtecan demonstrated an objective response rate (ORR) of 27% as assessed by blinded independent central review (BICR). All responses were partial (n=11) and 56% of patients achieved stable disease (n=23). The disease control rate (DCR) was 85% and median progression-free survival (PFS) was 8.3 months (95% confidence interval [CI]: 5.5-11.1). With median follow-up of 13.7 months (range, 9-16), the median duration of response (DoR; 95% CI: 4.4-NE) and the median overall survival (OS) had not been reached with 59% of patients alive for more than one year.

“Patients with HR positive, HER2 low or negative metastatic breast cancer who are not eligible for endocrine therapy or have exhausted treatment options have a poor prognosis,” said presenting author Funda Meric-Bernstam, MD, Chair of the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center. “These preliminary results with datopotamab deruxtecan in patients with heavily pretreated HR positive, HER2 low or negative metastatic breast cancer are encouraging and warrant further evaluation in this setting.”

The safety profile of datopotamab deruxtecan was consistent with previous data with no new safety signals identified. The most common grade 3 or higher treatment-emergent adverse events (TEAEs) were decreased lymphocyte count (15%), stomatitis (10%), anemia (7%), dyspnea (2%) and fatigue (2%). Serious TEAEs were observed in six (15%) patients, including one death due to dyspnea that was not considered treatment-related. Treatment discontinuations due to an adverse event occurred in five (12%) patients. No cases of grade 3 or higher diarrhea or febrile neutropenia were observed. One case of grade 3 interstitial lung disease was adjudicated as treatment-related.

“These results add to the growing body of data demonstrating the potential of datopotamab deruxtecan to treat certain types of metastatic breast cancer,” said Mark Rutstein, MD, Global Head, Oncology Clinical Development, Daiichi Sankyo. “We look forward to the continued evaluation of our TROP2 directed antibody drug conjugate, including comparisons to standard therapy in earlier lines of treatment for HR positive, HER2 low or negative metastatic breast cancer through our ongoing TROPION-Breast01 phase 3 trial.”

“Many of these patients with metastatic breast cancer in TROPION-PanTumor01 had exhausted most of their available treatment options, having received a striking median of five prior regimens, including a CDK4/6 inhibitor for nearly all patients,” said Cristian Massacesi, MD, Chief Medical Officer and Oncology Chief Development Officer, AstraZeneca. “These promising results with datopotamab deruxtecan in such a heavily pretreated patient population support our strong belief that this TROP2 directed antibody drug conjugate has the potential to improve outcomes for patients with HR positive, HER2 low or negative breast cancer in this, and possibly earlier settings.”

Patients in this cohort were heavily pretreated, receiving a median of five prior lines of treatment in the metastatic setting (range, 3-10). Prior treatments included CDK4/6 inhibitors (95%), capecitabine (83%), taxanes (59%), anthracyclines (54%), neoadjuvant chemotherapy (37%), mTOR inhibitors (29%) and PI3KCA inhibitors (20%). As of data cut-off on July 22, 2022, five patients remained on study treatment.

Summary of Results

Efficacy Measure

Datopotamab Deruxtecan (6 mg/kg)n=41

Confirmed ORR, %i,ii

27% (n=11)

PR, %

27% (n=11)

SD, %

56% (n=23)

Non-CR/non-PD, %

2% (n=1)

PD, %

12% (n=5)

NE, %

2% (n=1)

DCR, %i,iii

85% (n=35)

Median DoR (months) (95% CI)i

NE (4.4-NE)

Median PFS (months) (95% CI)i

8.3 months (5.5-11.1)

Median OS (months)

Not reached

CI, confidence interval; CR, clinical response; DCR, disease control rate; DoR, duration of response; NE, not evaluable; ORR, objective response rate; OS, overall survival; PD, progressive disease; PFS, progression-free survival; PR, partial response; SD, stable disease

i As assessed by BICR

ii ORR is (CR + PR)

iii DCR is (CR + PR + SD + non-CR/non-PD)

Daiichi Sankyo and AstraZeneca have a broad clinical development program for datopotamab deruxtecan in breast cancer, including the ongoing pivotal TROPION-Breast01 phase 3 trial evaluating datopotamab deruxtecan in patients with HR positive, HER2 low or negative, inoperable or metastatic breast cancer previously treated with chemotherapy.

About TROPION-PanTumor01
TROPION-PanTumor01 is a first-in-human, open-label, two-part, multicenter phase 1 trial evaluating the safety and preliminary efficacy of datopotamab deruxtecan in patients with advanced solid tumors that have relapsed or are refractory to standard treatment or for which no standard treatment is available. The dose escalation portion of the trial enrolled patients with non-small cell lung cancer (NSCLC) to assess the safety and efficacy of datopotamab deruxtecan to determine the recommended dose for expansion (6 mg/kg). The dose expansion part of TROPION-PanTumor01 is enrolling several different cohorts including patients with NSCLC, triple negative breast cancer (TNBC), HR positive, HER2 low or negative breast cancer, small cell lung cancer, urothelial, gastric, pancreatic, castration-resistant prostate and esophageal cancer.

Safety endpoints include dose-limiting toxicities and serious adverse events. Efficacy endpoints include ORR, DoR, time to response, PFS and OS. Pharmacokinetic, biomarker and immunogenicity endpoints also are being evaluated.

About HR Positive, HER2 Low or Negative Breast Cancer
Breast cancer is the most common cancer and one of the leading causes of cancer-related deaths worldwide.3 More than two million breast cancer cases were diagnosed in 2020 with nearly 685,000 deaths globally.3

Breast cancer is considered HR positive, HER2 low or negative when the tumors test positive for estrogen and/or progesterone hormone receptors and low for HER2 (measured as a HER2 score of IHC 1+ or IHC 2+/ISH-) or negative for HER2 (measured as IHC 0).1,4 This subtype accounts for approximately 70% of diagnosed breast cancer cases and is associated with lower survival rates with 30% of patients anticipated to live beyond five years after diagnosis.1 Current standard of care treatment for patients with HR positive, HER2 low or negative metastatic breast cancer that progress on hormone therapy-based regimens is sequential single-agent chemotherapy, which is associated with a low median PFS of less than 10 months and OS of less than two years, underscoring the need for additional treatment options.2,5,6,7

TROP2 (trophoblast cell-surface antigen 2) is a transmembrane glycoprotein that is broadly expressed in several types of solid tumors, including HR positive, HER2 low or negative breast cancer.8,9 TROP2 expression is an unfavorable prognostic factor for overall survival in all types of breast cancer.8

About Datopotamab Deruxtecan (Dato-DXd)
Datopotamab deruxtecan (Dato-DXd) is an investigational TROP2 directed ADC. Designed using Daiichi Sankyo’s proprietary DXd ADC technology, datopotamab deruxtecan is one of the three lead ADCs in the oncology pipeline of Daiichi Sankyo, and one of the most advanced programs in AstraZeneca’s ADC scientific platform. Datopotamab deruxtecan is comprised of a humanized anti-TROP2 IgG1 monoclonal antibody, developed in collaboration with Sapporo Medical University, attached to a number of topoisomerase I inhibitor payloads, an exatecan derivative, via tetrapeptide-based cleavable linkers.

A comprehensive development program called TROPION is underway globally with more than 10 trials evaluating the efficacy and safety of datopotamab deruxtecan across multiple TROP2 targetable tumors, including NSCLC, TNBC and HR positive, HER2 low or negative breast cancer. Trials in combination with other anticancer treatments, such as immunotherapy, are also underway.

About the Daiichi Sankyo and AstraZeneca Collaboration
Daiichi Sankyo and AstraZeneca entered into a global collaboration to jointly develop and commercialize datopotamab deruxtecan in July 2020, except in Japan where Daiichi Sankyo maintains exclusive rights. Daiichi Sankyo is responsible for the manufacturing and supply of datopotamab deruxtecan.

About Daiichi Sankyo
Daiichi Sankyo is dedicated to creating new modalities and innovative medicines by leveraging our world-class science and technology for our purpose “to contribute to the enrichment of quality of life around the world.” In addition to our current portfolio of medicines for cancer and cardiovascular disease, Daiichi Sankyo is primarily focused on developing novel therapies for people with cancer as well as other diseases with high unmet medical needs. With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 16,000 employees around the world draw upon a rich legacy of innovation to realize our 2030 Vision to become an “Innovative Global Healthcare Company Contributing to the Sustainable Development of Society.” For more information, please visit: www.daiichisankyo.com.

References:

1 National Cancer Institute. SEER cancer stat facts: female breast cancer subtypes. Accessed December 2022.
2 NCCN Treatment Guidelines for Breast Cancer. Version 4.2022.
3 Sung H, et al. CA Cancer J Clin. 2021;10.3322/caac.21660.
4 Iqbal N, et al. Mol Biol Int. 2014;852748.
5 Cortes J, et al. Lancet. 2011;377:914-923.
6 Yuan P, et al. Eur J Cancer. 2019;112:57-65.
7 Jerusalem G, et al. JAMA Oncol. 2018;4(10):1367–1374.
8Goldenberg D, et al. Oncotarget. 2018;9(48): 28989-29006.
9 Zaman S, et al. Onco Targets Ther. 2019;12:1781–1790.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contacts:

Global/US:
Rose Talarico
Daiichi Sankyo, Inc.
rtalarico@dsi.com
+1 973 775 0838 (mobile)

EU:
Simone Jendsch-Dowé
Daiichi Sankyo Europe GmbH
simone.dowe@daiichi-sankyo.eu
+49 (89) 78080 (office)

Japan:
Koji Ogiwara
Daiichi Sankyo Co., Ltd.
ogiwara.koji.ay@daiichisankyo.co.jp
+81 3 6225 1126 (office)

Investor Relations:
DaiichiSankyoIR@daiichisankyo.co.jp

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Belkin Introduces Samsung Approved Screen Protectors for New Samsung Galaxy S23, S23+ and S23 Ultra Smartphones2.2.2023 01:00:00 CET | Press release

Belkin, a global consumer electronics leader in device protection, today introduces its ScreenForce™ TrueClear Curve screen protectors for the new Samsung Galaxy S23 series. These products have not only passed Belkin’s rigorous design and engineering quality tests but have also received the “Designed for Samsung” badge through the Samsung Mobile Accessory Partnership Program (SMAPP). “Belkin has led the accessories market in innovation and technology leadership for 40 years. People trust us to build the world’s best products to connect, power and protect their devices, and to put our customers and partners first,” said Steve Malony, CEO, Belkin. “Having Samsung’s additional stamp of approval allows our customers to have comfort and confidence that a Belkin product was designed perfectly for their brand-new device.” Belkin ScreenForce™ TrueClear Curve Blue Light Filter Screen Protectors are available for all three new Samsung devices and are engineered to accentuate the design of the de

Airswift Technology and Cloud Payments Partner to Enable Instant Access to Crypto with VISA and MasterCard1.2.2023 23:04:00 CET | Press release

Airswift Technology Limited, a leading Web3.0 native payment company, and Cloud Payments, a digital payments and banking technology platform provider have joined forces to enable cryptocurrency spenders with instant access to crypto at the points-of-sale using VISA and MasterCard payment methods. The collaboration will simplify crypto-based purchases by providing crypto on-ramping and NFT purchasing using VISA and MasterCard with optimized exchange rates. This offers crypto spenders increased convenience when shopping for retail goods and digital assets. “Millions of Web2.0 consumers are ready to onboard to Web3.0, but are not familiar with existing Decentralized Finance (DeFi) on-ramps,” said Dr. Yan Zhang, co-founder and CEO of Airswift. “So we’ve worked together to integrate Cloud Payments' simple, credit-card based crypto purchasing tools into our easy-to-use crypto payment platform. This feature lets you seamlessly on-ramp to and spend crypto right at the checkout without ever lea

Swave Photonics, QART Medical, and PhosPrint win big at 2023 SPIE Startup Challenge1.2.2023 22:02:00 CET | Press release

Yesterday, at a ceremony during SPIE Photonics West, Swave Photonics – with their Holographic eXtended Reality chips based on proprietary diffractive photonics technology – was announced the winner of the $10,000 top prize at the 13th annual SPIE Startup Challenge. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230201005834/en/ Jenoptik’s Ralf Kuschnereit, far left, Swave Co-Founder and Chief Product Officer Theo Marescaux, Swave CEO Mike Noonen, and 2023 SPIE Vice President Peter de Groot. Credit: Joey Cobbs. QART Medical, utilizing biophotonics and data for 3D analysis of sperm cells during IVF, received $5,000 for second place. PhosPrint came in third, winning $2,500, with their novel bioprinting technology that repairs in vivo human tissue during surgery. All cash prizes are provided by SPIE Startup Challenge Founding Partner Jenoptik. The SPIE Startup Challenge, a pitchcompetition held annually by SPIE, the internationa

Q4 Inc. to Report Fourth Quarter 2022 Results on March 1st1.2.2023 22:00:00 CET | Press release

Q4 Inc. (TSX: QFOR), ("Q4" or the "Company") a leading capital markets communications platform, plans to release its fourth quarter and full year 2022 financial results before the market opens on Wednesday, March 1, 2023. In conjunction with this release, the company will hold a video webcast led by CEO Darrell Heaps, on the Q4 Virtual Events Platform at 9:30 a.m. ET on March 1, 2023. Q4 2022 Earnings Release and Conference Call Details Participants can register in advance or access the webcast live at https://events.q4inc.com/attendee/712032670. Supplemental materials will be available at least fifteen minutes prior to the start of the event. A replay of the webcast will be available at investors.q4inc.com shortly after the event concludes. Audience questions will be taken real-time via the Q4 Platform. Investors can also submit their questions in advance to ir@q4inc.com or via our IR website. We will do our best to respond to your questions either on the webcast, if time permits or s

Tanium Appoints Dan Streetman as Chief Executive Officer1.2.2023 20:00:00 CET | Press release

Tanium, a leading IT operations and security management company and the premier supplier of converged endpoint management (XEM), today announced the appointment of Dan Streetman to the role of chief executive officer. Orion Hindawi, who is the co-founder and current CEO of Tanium, will assume the role of executive chairman. In this new role, Orion will continue to drive the strategic vision and technical innovation at Tanium as well as continue his engagement with Tanium’s strategic partners and customers. David Hindawi, co-founder of Tanium, will transition to chairman emeritus. In his new role, Streetman will continue to strengthen Tanium’s commitment to protecting enterprises, organizations, and their people, while fortifying and evolving the company’s customer-facing operations, partner strategy, product strategy, and development. Streetman will build on the strong market momentum that Tanium has seen, including coming off a record fiscal year in terms of revenue and new customer g